Answers are grounded in this paper and cite their sources.
The metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-phosphate (F-araAMP), a soluble nucleoside analog with promising antitumor activity, has been studied in mice bearing P388 leukemia. Upon i.p. injection of an LD10 dose (1485 mg/kg) in tumor-bearing mice, F-araAMP disappeared from the ascitic fluid with a T1/2 of 1.2 h. This was accompanied by the appearance of 9-beta-D-arabinofuranosyl-2-fluoroadenine and lesser amounts of 9-beta-D-arabinofuranosyl-2-fluorohypoxanthine in both the ascitic fluid and plasma. The principal active metabolite, 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-triphosphate, accumulated to approximately 1 mM in P388 cells, a concentration nearly 20-fold greater than that of the bone marrow or intestinal mucosa. DNA synthesis was inhibited to a similar extent in tumor and host tissues, but the duration of maximum inhibition was twice as long in P388 cells. 2-Fluoro-ATP, a second toxic metabolite, accumulated to 27 microM in P388 cells and was eliminated with a T1/2 of 3.7 h. The contributions of both 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-triphosphate and 2-fluoro-ATP to the cytotoxicity and therapeutic action of F-araAMP should be considered in evaluations of the biochemical bases for these activities.
No takes yet. Share an insight, caveat, or question.
Avramis et al. (1983) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: